CHEK

In a report released on September 15, Jason Kolbert from Dawson James maintained a Hold rating on Check-Cap (CHEK - Research Report). The company's shares closed last Friday at $0.31.According to TipRanks, Kolbert is an analyst with an average return of -2.4% and a 35.31% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Can-Fite BioPharma, Sorrento Therapeutics, and Daré Bioscience.Currently, the analyst consensus on Check-Cap is a Moderate Buy with an average price target of $3.00.See the top stocks recommended by analysts >>The company has a one-year high of $1.31 and a one-year low of $0.29. Currently, Check-Cap has an average volume of 495.4K.
https://www.tipranks.com/news/blurbs/dawson-james-reaffirms-their-hold-rating-on-check-cap-chek?utm_source=advfn.com&utm_medium=referral